These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 28306363)

  • 1. Genome database mining for the discovery of novel lantibiotics.
    Sandiford SK
    Expert Opin Drug Discov; 2017 May; 12(5):489-495. PubMed ID: 28306363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perspectives on lantibiotic discovery - where have we failed and what improvements are required?
    Sandiford SK
    Expert Opin Drug Discov; 2015 Apr; 10(4):315-20. PubMed ID: 25697059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increasing the success rate of lantibiotic drug discovery by Synthetic Biology.
    Montalbán-López M; Zhou L; Buivydas A; van Heel AJ; Kuipers OP
    Expert Opin Drug Discov; 2012 Aug; 7(8):695-709. PubMed ID: 22680308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An overview of lantibiotic biosynthetic machinery promiscuity and its impact on antimicrobial discovery.
    Sandiford SK
    Expert Opin Drug Discov; 2020 Mar; 15(3):373-382. PubMed ID: 31941374
    [No Abstract]   [Full Text] [Related]  

  • 5. Advances in the arsenal of tools available enabling the discovery of novel lantibiotics with therapeutic potential.
    Sandiford SK
    Expert Opin Drug Discov; 2014 Mar; 9(3):283-97. PubMed ID: 24410252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current developments in lantibiotic discovery for treating Clostridium difficile infection.
    Sandiford SK
    Expert Opin Drug Discov; 2019 Jan; 14(1):71-79. PubMed ID: 30479173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving the attrition rate of Lanthipeptide discovery for commercial applications.
    Geng M; Smith L
    Expert Opin Drug Discov; 2018 Feb; 13(2):155-167. PubMed ID: 29195488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multipronged approach for engineering novel peptide analogues of existing lantibiotics.
    Escano J; Smith L
    Expert Opin Drug Discov; 2015; 10(8):857-70. PubMed ID: 26004576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel LanT associated lantibiotic clusters identified by genome database mining.
    Singh M; Sareen D
    PLoS One; 2014; 9(3):e91352. PubMed ID: 24621781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent development of computational resources for new antibiotics discovery.
    Kim HU; Blin K; Lee SY; Weber T
    Curr Opin Microbiol; 2017 Oct; 39():113-120. PubMed ID: 29156309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and development of lantibiotics; antimicrobial agents that have significant potential for medical application.
    Al-Mahrous MM; Upton M
    Expert Opin Drug Discov; 2011 Feb; 6(2):155-70. PubMed ID: 22647134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequence-based analysis and prediction of lantibiotics: A machine learning approach.
    Poorinmohammad N; Hamedi J; Moghaddam MHAM
    Comput Biol Chem; 2018 Dec; 77():199-206. PubMed ID: 30342319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lantibiotics: promising candidates for future applications in health care.
    Dischinger J; Basi Chipalu S; Bierbaum G
    Int J Med Microbiol; 2014 Jan; 304(1):51-62. PubMed ID: 24210177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bovicin HJ50-like lantibiotics, a novel subgroup of lantibiotics featured by an indispensable disulfide bridge.
    Wang J; Ma H; Ge X; Zhang J; Teng K; Sun Z; Zhong J
    PLoS One; 2014; 9(5):e97121. PubMed ID: 24821187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isolation and characterization of NAI-802, a new lantibiotic produced by two different Actinoplanes strains.
    Simone M; Monciardini P; Gaspari E; Donadio S; Maffioli SI
    J Antibiot (Tokyo); 2013 Feb; 66(2):73-8. PubMed ID: 23168402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in synthetic analogues of lantibiotics: What can we learn from these?
    Tabor AB
    Bioorg Chem; 2014 Aug; 55():39-50. PubMed ID: 24877613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating the feasibility of lantibiotics as an alternative therapy against bacterial infections in humans.
    van Heel AJ; Montalban-Lopez M; Kuipers OP
    Expert Opin Drug Metab Toxicol; 2011 Jun; 7(6):675-80. PubMed ID: 21521092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The biology of lantibiotics from the lacticin 481 group is coming of age.
    Dufour A; Hindré T; Haras D; Le Pennec JP
    FEMS Microbiol Rev; 2007 Mar; 31(2):134-67. PubMed ID: 17096664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An update on the use of C. elegans for preclinical drug discovery: screening and identifying anti-infective drugs.
    Kim W; Hendricks GL; Lee K; Mylonakis E
    Expert Opin Drug Discov; 2017 Jun; 12(6):625-633. PubMed ID: 28402221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brominated Variant of the Lantibiotic NAI-107 with Enhanced Antibacterial Potency.
    Cruz JC; Iorio M; Monciardini P; Simone M; Brunati C; Gaspari E; Maffioli SI; Wellington E; Sosio M; Donadio S
    J Nat Prod; 2015 Nov; 78(11):2642-7. PubMed ID: 26512731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.